Oncology · 1975
Allogeneic bone marrow (hematopoietic stem cell) transplantation as curative therapy (Thomas)
Before E. Donnall Thomas's work in Seattle, a diagnosis of acute leukemia or severe aplastic anemia in an otherwise healthy adult was essentially a death sentence. Conventional chemotherapy could produce remissions, but durable cures were rare, and the bone marrow itself was often the source of the malignancy. The idea of destroying the marrow entirely with high-dose chemoradiotherapy and replacing it with a donor's cells had been explored in animals since the 1950s, but early attempts in humans failed because the immunological obstacles, graft rejection and graft-versus-host disease, were not yet understood well enough to manage.
Thomas's group at the Fred Hutchinson Cancer Research Center in Seattle spent years refining the protocol. The key advances included better HLA typing to identify matched sibling donors, and methotrexate-based regimens to suppress graft-versus-host disease after infusion. Their 1975 report in the New England Journal of Medicine described 100 patients with advanced leukemia or aplastic anemia who had received marrow from HLA-matched siblings after high-dose conditioning. A meaningful fraction achieved durable remission, a result that had not been reproducibly demonstrated before.
Graft-versus-host disease remained the central danger. Donor T cells attacking host tissue could produce a severe, sometimes fatal syndrome affecting the skin, gut, and liver. Rainer Storb, working alongside Thomas, focused on refining immunosuppressive conditioning to reduce this toxicity without losing the graft-versus-leukemia effect that made transplantation therapeutically useful. Their collaboration over two decades systematically narrowed the margin between efficacy and harm.
The field confronted early skepticism from transplant centers that had seen only failures. Thomas's data were reproducible, and other centers eventually confirmed them. Subsequent work extended the technique to unrelated donors identified through registries, broadening eligibility beyond the minority of patients with matched siblings. The National Marrow Donor Program, established in the United States in 1987, was a direct institutional consequence of that need.
Thomas received the Nobel Prize in Physiology or Medicine in 1990. Allogeneic stem cell transplantation is now standard of care for AML, ALL, MDS, and aplastic anemia. More than 50,000 procedures are performed annually worldwide, and peripheral blood stem cell mobilization has largely replaced surgical marrow harvesting, though the biological principles Thomas established remain unchanged.
Key People
- E. Donnall Thomas — Seattle oncologist who developed the clinical transplant protocol; 1990 Nobel laureate.
- Rainer Storb — Thomas's collaborator on immunosuppression protocols at the Fred Hutchinson Cancer Center.
- Joseph Ferrebee — Collaborator whose early animal marrow transplant work informed Thomas's clinical approach.
- Paul Terasaki — Immunologist who developed HLA typing methods critical to donor matching.
N Engl J Med, 1975
Related landmarks
- 1976 · Harald zur Hausen hypothesis linking HPV to cervical cancer (Oncology)
- 1971 · Health Insurance Plan (HIP) of Greater New York mammography trial (Oncology)
- 1979 · Total Therapy / combination treatment curing childhood ALL (Oncology)
- 1970 · MOPP combination chemotherapy for Hodgkin's disease (Oncology)